Wei Y. Chan

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.

RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.

Journal: Science advances
Published: August 12, 2026

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.

Journal: British journal of haematology
Published: April 14, 2026

An Improved m6A-ELISA for Quantifying N6 -methyladenosine in Poly(A)-purified mRNAs.

An Improved m6A-ELISA for Quantifying N6 -methyladenosine in Poly(A)-purified mRNAs.

Journal: Bio-protocol
Published: February 13, 2025

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Journal: British journal of haematology
Published: January 21, 2025

Budding yeast as an ideal model for elucidating the role of N6-methyladenosine in regulating gene expression.

Budding yeast as an ideal model for elucidating the role of N6-methyladenosine in regulating gene expression.

Journal: Yeast (Chichester, England)
Published: September 28, 2023

Multi-signal regulation of the GSK-3β homolog Rim11 controls meiosis entry in budding yeast.

Multi-signal regulation of the GSK-3β homolog Rim11 controls meiosis entry in budding yeast.

Journal: The EMBO journal
Published: September 28, 2023

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Journal: Blood
Published: June 20, 2023

Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.

Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.

Journal: Leukemia & lymphoma
Published: May 16, 2022

Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.

Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.

Journal: British journal of haematology
Published: April 25, 2022

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

Journal: British journal of haematology
Published: October 11, 2021

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.

Journal: British journal of haematology
Published: August 12, 2021

Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.

Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.

Journal: British journal of haematology
Published: February 17, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026